you are here: Home News Injectables

Injectables

Gland Pharma: Does it still offer value after a strong run?
Concord Biotech: Time to take some profit off the table?
Weekly Tactical Pick: A pharma stock that plays by the rulebook
Syngene: Multi-year contract with Zoetis adds to long-term visibility
Gland Pharma: What do acute supply shortages mean for the business & investors?
Gland Pharma: Track this inorganic play for the near term
Cadila: Unfolding vaccine opportunity can offset US headwinds
Aurobindo Pharma: Termination of inorganic bet eases capital allocation worries
Lupin: Margin guidance downgrade keeps us cautious
Cadila: More a COVID hedge in the near term
Glenmark Life Sciences IPO: Traction in complex APIs holds re-rating potential
Ideas For Profit | Gland Pharma: Steady earnings compounder; invest on dips
Gland Pharma’s new product play for FY22 holds a lot of promise
Aurobindo Pharma's board to consider demerger of its Injectables business soon
Lupin: New launches and market share gains are likely to override pricing erosion
Gland Pharma Q3: Strong and clean play on global generic injectables; accumulate
Gland Pharma: Post IPO listing, what should investors do?
Gland Pharma IPO: Much more than a Heparin play; subscribe
Aurobindo Pharma: Shot in the arm for Covid vaccine development programme
Aurobindo: Traction in complex generics is vital to its health
Pfizer plans to bring more global drugs to India
Fosun Pharma best fit due to global presence, size: Gland Pharma
Citi bullish on Aurobindo Pharma; says stock can re-rate
Lupin scouts for acquisitions in US
Wockhardt hits 52-week low on UK import alert

English

Markets

News

Personal Finance

Mutual Funds

Commodities

Media

Invest Now

Specials

Injectables

Gland Pharma: Does it still offer value after a strong run?

Concord Biotech: Time to take some profit off the table?

Weekly Tactical Pick: A pharma stock that plays by the rulebook

Syngene: Multi-year contract with Zoetis adds to long-term visibility

Gland Pharma: What do acute supply shortages mean for the business & investors?

Gland Pharma: Track this inorganic play for the near term

Cadila: Unfolding vaccine opportunity can offset US headwinds

Aurobindo Pharma: Termination of inorganic bet eases capital allocation worries

Lupin: Margin guidance downgrade keeps us cautious

Cadila: More a COVID hedge in the near term

Glenmark Life Sciences IPO: Traction in complex APIs holds re-rating potential

Ideas For Profit | Gland Pharma: Steady earnings compounder; invest on dips

Gland Pharma’s new product play for FY22 holds a lot of promise

Aurobindo Pharma's board to consider demerger of its Injectables business soon

Lupin: New launches and market share gains are likely to override pricing erosion

Gland Pharma Q3: Strong and clean play on global generic injectables; accumulate

Gland Pharma: Post IPO listing, what should investors do?

Gland Pharma IPO: Much more than a Heparin play; subscribe

Aurobindo Pharma: Shot in the arm for Covid vaccine development programme

Aurobindo: Traction in complex generics is vital to its health

Pfizer plans to bring more global drugs to India

Fosun Pharma best fit due to global presence, size: Gland Pharma

Citi bullish on Aurobindo Pharma; says stock can re-rate

Lupin scouts for acquisitions in US

Wockhardt hits 52-week low on UK import alert